KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEquity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Gsk (GSK) EBIT (2016 - 2025)

Historic EBIT for Gsk (GSK) over the last 17 years, with Q3 2025 value amounting to $3.5 billion.

  • Gsk's EBIT rose 132448.73% to $3.5 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $13.0 billion, marking a year-over-year increase of 3763.55%. This contributed to the annual value of $5.1 billion for FY2024, which is 3873.42% down from last year.
  • According to the latest figures from Q3 2025, Gsk's EBIT is $3.5 billion, which was up 132448.73% from $2.7 billion recorded in Q2 2025.
  • Over the past 5 years, Gsk's EBIT peaked at $5.2 billion during Q4 2023, and registered a low of $245.6 million during Q3 2024.
  • Its 5-year average for EBIT is $2.4 billion, with a median of $2.5 billion in 2023.
  • As far as peak fluctuations go, Gsk's EBIT crashed by 9354.66% in 2021, and later skyrocketed by 132448.73% in 2025.
  • Quarter analysis of 5 years shows Gsk's EBIT stood at $663.2 million in 2021, then skyrocketed by 496.7% to $4.0 billion in 2022, then skyrocketed by 32.44% to $5.2 billion in 2023, then dropped by 23.21% to $4.0 billion in 2024, then dropped by 13.09% to $3.5 billion in 2025.
  • Its EBIT was $3.5 billion in Q3 2025, compared to $2.7 billion in Q2 2025 and $2.8 billion in Q1 2025.